The IGF-1R Inhibitor NVP-AEW541 Causes Insulin-Independent and Reversible Cardiac Contractile Dysfunction

Autor: Christina Schenkl, Andrea Schrepper, Estelle Heyne, Torsten Doenst, Michael Schwarzer

Publikováno v: Biomedicines, Vol 10, Iss 8, p 2022 (2022)

The antitumor treatment NVP-AEW541 blocks IGF-1R. IGF-1R signaling is crucial for cardiac function, but the cardiac effects of NVP-AEW541 are ill defined. We assessed NVP-AEW541′s effects on cardiac function and insulin response in vivo and in isol

Externí odkaz: https://doaj.org/article/b7b91b024cc14b5f8f5e9898a3d64a98

The IGF-1R Inhibitor NVP-AEW541 Causes Insulin-Independent and Reversible Cardiac Contractile Dysfunction

Autor: Schwarzer, Christina Schenkl, Andrea Schrepper, Estelle Heyne, Torsten Doenst, Michael

Publikováno v: Biomedicines; Volume 10; Issue 8; Pages: 2022

The antitumor treatment NVP-AEW541 blocks IGF-1R. IGF-1R signaling is crucial for cardiac function, but the cardiac effects of NVP-AEW541 are ill defined. We assessed NVP-AEW541′s effects on cardiac function and insulin response in vivo and in isol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=multidiscipl::b09464cfa706dc6d790532a22a349a3c

Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain

Autor: Liu Shuxian, Lu Daiqiang, Qianqian Hua, Linyan Cheng, Feng Tan, Yuan Tian, Helin Yu, Wu Mimi, Cao Jiaxin, Xin Hu, Yinqi Chen

Publikováno v: Parasites & Vectors
Parasites & Vectors, Vol 13, Iss 1, Pp 1-13 (2020)

Background Toxoplasma gondii is a zoonotic pathogen that causes toxoplasmosis and leads to serious public health problems in developing countries. However, current clinical therapeutic drugs have some disadvantages, such as serious side effects, a lo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::081ddc38f3f39fa46ec4bc1f17fe160f
http://europepmc.org/articles/PMC7216583

Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer

Autor: Richard J. Pietras, Yanyuan Wu, Jaydutt V. Vadgama, Rudy Sanchez, Kay Foos, Nalo Hamilton, David Austin, Brittney Chau, Diana C. Márquez-Garbán

Publikováno v: International Journal of Molecular Sciences, Vol 18, Iss 11, p 2305 (2017)
International Journal of Molecular Sciences; Volume 18; Issue 11; Pages: 2305
International journal of molecular sciences, vol 18, iss 11
International Journal of Molecular Sciences

Triple-negative breast cancer (TNBC) occurs in 10-15% of all breast cancer patients, yet it accounts for about half of all breast cancer deaths. There is an urgent need to identify new antitumor targets to provide additional treatment options for pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::459c39bee187de5b972f0f81b63cd801
https://www.mdpi.com/1422-0067/18/11/2305

Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

Autor: Alexandra Hamacher, Katharina Gohr, Matthias U. Kassack, Laura H. Engelke

Publikováno v: BMC Cancer
BMC Cancer, Vol 17, Iss 1, Pp 1-13 (2017)

Background Widely established targeted therapies directed at triple negative breast cancer (TNBC) are missing. Classical chemotherapy remains the systemic treatment option. Cisplatin has been tested in TNBC but bears the disadvantage of resistance de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e34a372ac29b3f5622ee5cd5f1738a52
https://pubmed.ncbi.nlm.nih.gov/29100507